Catabasis Pharmaceuticals has shared the latest edition of their community newsletter, including information about edasalonexent and COVID-19, and responses to questions they have received.
March 26, 2020 / Clinical Trials
Catabasis Pharmaceuticals has shared the latest edition of their community newsletter, including information about edasalonexent and COVID-19, and responses to questions they have received.